18F-FGLN PET Imaging for Pulmonary Arterial Hypertension

Phase-Based Progress Estimates
Montefiore Hospital Clinical and Translational Research Center, Pittsburgh, PA
Pulmonary Arterial Hypertension+5 More
18F-FGLN PET Imaging - DiagnosticTest
All Sexes
What conditions do you have?

Study Summary

This trial will study whether [F-18]FGln can be used as a non-invasive imaging biomarker to detect early stages of pulmonary arterial hypertension (PAH), a disease affecting the blood vessels of the lung. The trial will use 18F-FGLN PET Imaging to treat Pulmonary Arterial Hypertension, rather than a placebo. This treatment is free for patients who participate in the trial. This form of imaging has been previously approved by the FDA for treating a different condition.

Eligible Conditions

  • Pulmonary Arterial Hypertension
  • Pulmonary arterial hypertension

Treatment Effectiveness

Effectiveness Progress

1 of 3

Other trials for Pulmonary Arterial Hypertension

Study Objectives

1 Primary · 0 Secondary · Reporting Duration: 90 minutes

90 minutes
SUV or image-based threshold of 18F-FGNnon-diseased controls

Trial Safety

Safety Progress

1 of 3

Other trials for Pulmonary Arterial Hypertension

Trial Design

1 Treatment Group

18F-FGLN PET Imaging
1 of 1
Experimental Treatment

50 Total Participants · 1 Treatment Group

Primary Treatment: 18F-FGLN PET Imaging · No Placebo Group · Phase < 1

18F-FGLN PET ImagingExperimental Group · 2 Interventions: (18F)FPGLU, 18F-FGLN PET Imaging · Intervention Types: Drug, DiagnosticTest

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: 90 minutes
Closest Location: Montefiore Hospital Clinical and Translational Research Center · Pittsburgh, PA
Photo of Pittsburgh 1Photo of Pittsburgh 2Photo of Pittsburgh 3
2010First Recorded Clinical Trial
1 TrialsResearching Pulmonary Arterial Hypertension
1 CompletedClinical Trials

Who is running the clinical trial?

Stephen Y. ChanLead Sponsor
National Heart, Lung, and Blood Institute (NHLBI)NIH
3,556 Previous Clinical Trials
46,915,045 Total Patients Enrolled
20 Trials studying Pulmonary Arterial Hypertension
2,234 Patients Enrolled for Pulmonary Arterial Hypertension
BayerIndustry Sponsor
2,132 Previous Clinical Trials
23,823,646 Total Patients Enrolled
27 Trials studying Pulmonary Arterial Hypertension
6,326 Patients Enrolled for Pulmonary Arterial Hypertension
Stephen ChanPrincipal InvestigatorUniversity of Pittsburgh

Eligibility Criteria

Age 18+ · All Participants · 3 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 9th, 2021

Last Reviewed: August 12th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.